The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient
In rodent models, vildagliptin enhanced blood flow recovery and capillary density in ischemic limbs with accompanying increases in endothelial nitric-oxide synthase [119] and prevented left ventricular hypertrophy caused by continuous beta-adrenergic stimulation by isoproterenol [120]
Adylxin FDA Safety Label Change Bydureon BCISE extended-release (exenatide synthetic) subcutaneous weekly injection FDA Approval Year: 2017 Bydureon Extended Release Safety Label Change Byetta (exenatide synthetic) subcutaneous twice-daily injection FDA Approval Year: 2005 Byetta FDA Safety Label Change Mounjaro (tirzepatide) subcutaneous weekly injection FDA Approval Year: 2022 The Gastrointestinal Adverse Reaction section added that a small number of patients have reported the experience of dysgeusia (altered sense of taste)
Small fluctuations are normal, but early changes help identify whether calorie intake, physical activity, sleep, or stress are shifting
Think of them as a powerful tool for fat reduction, not for altering skin texture
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
